Plain-English fact sheet
Bremelanotide
Also known as Vyleesi, PT-141
Bremelanotide is FDA approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women—not as a universal libido or performance enhancer.
Quick answer
Bremelanotide is FDA approved for a specific diagnosis: acquired, generalized hypoactive sexual desire disorder in premenopausal women when the low desire is not explained by another condition, relationship problem, or medication. It is not approved to enhance sexual performance or for use in men or postmenopausal women.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Bremelanotide?
Bremelanotide is a synthetic cyclic peptide that activates melanocortin receptors involved in central nervous system signaling.
Its approval is tied to a defined diagnosis, population, product, and outcome—not the broader online label PT-141.
Why are people interested in it?
It is an unusual approved peptide that acts through central desire pathways rather than directly changing blood flow.
Online claims often erase the label's population limits and significant cardiovascular, nausea, and pigmentation warnings.
Current regulatory status
Vyleesi has been FDA approved since 2019 for acquired, generalized hypoactive sexual desire disorder in specified premenopausal women. The label explicitly excludes sexual-performance enhancement and use in men or postmenopausal women.
What is it approved for?
- Acquired, generalized hypoactive sexual desire disorder in eligible premenopausal women under the Vyleesi label
What is it being studied for?
Investigational areas
- Other sexual-function populations outside the approved label
Evidence snapshot
Two randomized Phase 3 trials support the scoped indication, with improvements in desire and distress measures. Evidence does not establish a universal libido or performance effect.
Potential benefits being researched
- Phase 3 trials found modest average improvements in sexual desire and distress compared with placebo in the labeled population.
- The clinical goal is diagnosis-specific improvement, not a general enhancement claim.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- The label warns about transient increases in blood pressure and reductions in heart rate and contraindicates use with uncontrolled hypertension or known cardiovascular disease.
- Nausea was common in pivotal trials; flushing, headache, vomiting, and injection-site reactions also occurred.
- Focal hyperpigmentation may occur and did not always resolve after stopping treatment in studies.
- The product can affect absorption of some oral medicines through delayed gastric emptying.
What we still do not know
- Benefit-risk balance in populations outside the label
- How well average trial changes translate into meaningful benefit for an individual
- Long-term outcomes with broader or more frequent exposure than studied
Plain-English takeaway
Bremelanotide is an approved peptide medicine, but the approved use is much narrower than the online PT-141 conversation. Diagnosis, population, cardiovascular risk, and the exact label matter.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA prescribing information: Vyleesi
Official indication, limitations, contraindications, warnings, and adverse reactions.
- 2FDA multidisciplinary review: Vyleesi
FDA's clinical and regulatory assessment supporting the 2019 approval.
- 3RECONNECT Phase 3 trials
Peer-reviewed report of the two pivotal randomized trials.